evidence based assessment and treatment of attention deficit hyperactivity disorder may 14, 2010...
Post on 20-Dec-2015
213 views
TRANSCRIPT
![Page 1: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/1.jpg)
Evidence Based Evidence Based Assessment and Treatment Assessment and Treatment
of Attention Deficit of Attention Deficit Hyperactivity DisorderHyperactivity Disorder
May 14, 2010May 14, 2010
Christopher K. Varley, M.D.Christopher K. Varley, M.D.
![Page 2: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/2.jpg)
Learning ObjectivesLearning Objectives• Refinement of diagnosis of ADHD
• Review of evidenced based treatment of ADHD
![Page 3: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/3.jpg)
Attention-Deficit/Hyperactivity DisorderA. Either (1) or (2):(1) six (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level: Inattention(a) often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other
activities(b) often has difficulty sustaining attention in tasks or play
activities(c) often does not seem to listen when spoken to directly
![Page 4: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/4.jpg)
Inattention (continued)(d)often does not follow through on instructions and fails to
finish schoolwork, chores, or duties in the workplace (not due to oppositional behavior or failure to understand instructions)
(e) often has difficulty organizing tasks and activities(f) often avoids, dislikes, or is reluctant to engage in tasks
that require sustained mental effort such as schoolwork or homework
(g)often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, books, or tools)
(h) is often easily distracted by extraneous stimuli(I) is often forgetful in daily activities
![Page 5: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/5.jpg)
(2) six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive and inconsistent with developmental level:
• Hyperactivity(a) often fidgets with hands or feet or squirms in seat(b) often leaves seat in classroom or in other situations in which remaining seated is expected(c) often runs about or climbs excessively in situations in which it is inappropriate (in adolescent or adults, may be limited to subjective feelings of restlessness)
![Page 6: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/6.jpg)
Hyperactivity (continued)(d) often has difficulty playing or engaging in leisure
activities quietly(e) is often “on the go” or often acts as if “driven by a
motor”(f) often talks excessively
• Impulsivity(a) often blurts out answers before questions have been
completed(b) often has difficulty awaiting turn(c) often interrupts or intrudes on others (e.g., butts into
conversations or games)
![Page 7: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/7.jpg)
B. Some hyperactive-impulsive or inattentive
symptoms that caused impairment were present
before age 7 years.
C. Some impairment from the symptoms is present in two or
more settings (e.g., at school (or work) and at home).
D. There must be clear evidence of clinically significant
impairment in social, academic, or occupations
functioning.
E. The symptoms do not occur exclusively during the course
of Pervasive Developmental Disorder, Schizophrenia, or
other Psychotic Disorder and are not better accounted for
by another mental disorder (e.g., Mood Disorder, Anxiety
Disorder, Dissociative Disorder, or a Personality Disorder).
![Page 8: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/8.jpg)
Code based on type:
314.01 Attention-Deficit/Hyperactivity Disorder, Combined Type: if both
Criteria A1 and A2 are met for the past 6 months
314.00 Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive
Type: if Criterion A1 is met by Criterion A2 is not met for the past 6 months
314.01 Attention-Deficit/Hyperactivity Disorder, predominantly Hyperactive-
Impulsive Type: if Criterion A2 is met but Criterion A1 is not met for the
past 6 months.
Coding note: For individuals (especially adolescents and adults) who currently
have symptoms that no longer meet full criteria, “In Partial Remission” should be
specified.
314.9 Attention-Deficit/Hyperactivity Disorder Not Otherwise Specified
This category is for disorders with prominent symptoms of inattention or
hyperactivity-impulsivity that do not meet criteria for Attention-Deficit/Hyperactivity
Disorder.
![Page 9: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/9.jpg)
ADHD DSM-V Changes Under Consideration
• Drop subtypes or drop primarily hyperactive impulsive and inattentive subtypes
• Change to age of onset on or before 12
• Nuanced changes in impulsivity criteria and criteria for adults
• Other disorders e.g. (Autism) will not exclude ADHD
![Page 10: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/10.jpg)
ATTENTION DEFICITHYPERACTIVITY DISORDER
Epidemiology1) Prevalence of 3-5% school-age children; 2-4%
adolescents2) Recent studies suggest as high as 10% of school-
age children
![Page 11: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/11.jpg)
ADHDEtiology
•No single cause to explain the vast majority of ADHD cases•Data support a biologic basis for ADHD•Future research may more fully elucidate the roles of neurophysiology, genetics, and environment in producing this disorder•Rising research on the Dopamine system, but not consistent findings
![Page 12: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/12.jpg)
Genetic Study Summary
• Adult relatives of children with ADHD have elevated rates of ADHD
• Child relatives of adults with ADHD have elevated rates of ADHD
• Molecular genetic findings are similar for children and adults
Faraone SV, et al. J Consult Clin Psychol:2000;68:830-842
![Page 13: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/13.jpg)
ADHD ETIOLOGY
Imaging Studies Summary • Results support prominent role of
- frontal lobe dysfunction in ADHD
- cortical-subcortical circuits
• Neuroimaging techniques have not been validated as tools for ADHD diagnosis or to inform treatment and are very expensive
![Page 14: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/14.jpg)
RATING SCALES• Narrow Band ADHD Scales
–Conners
–Vanderbilt
• Broad Band–CBCL
![Page 15: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/15.jpg)
Course of Disorder1) Earliest presentation is in toddlers
2) 2/3 of adolescents diagnosed as children
with ADHD have symptoms
3) At least 1/3 of adults diagnosed as children with
ADHD have important symptoms
4) Symptom course tends to be from motoric
in younger children to cognitive in
adolescents and adults
![Page 16: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/16.jpg)
ADHD: Persistence IntoAdolescence and Adulthood
0 20 40 60 80 100
Biederman et al (1996)
Hart et al (1995)
Barkley et al (1990)
Lambert et al (1987)
Weiss et al (1985)
![Page 17: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/17.jpg)
Comorbidity1) 40% of ADHD children have another
disruptive behavior disorder
2) 30% of ADHD children also have an anxiety
disorder or mood disorder
3) A similar pattern of comorbidity is present for
adolescents and adults. It is also especially
important to screen for alcohol and drug
abuse
4) 50% have Axis I condition of one or more
specific developmental disorders
![Page 18: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/18.jpg)
ADHD and Psychoactive Substance Use Disorders (PSUD)
• 4-year follow-up of a clinically referred sample of boys 6 to 17 years old at baseline (ADHD N=140; control N-120)
- no difference in the rate of alcohol or drug abuse between groups (15% vs 15%), mean age-early adolescence
- Risk for PSUD mediated by conduct disorder and bipolar disorder with or without ADHD
• Adults with ADHD (N-139) vs controls (N-268)- significantly greater lifetime rate of PSUD than controls (55% vs 27%)- Age of onset of PSUD in subjects with ADHD averaged 3 years earlier than controls (late adolescence/early adulthood)- ADHD was a significant risk factor independent of comorbid diagnoses
Biederman et al., JAACAP 1997-36:21Biederman et al., BioPsychiatry 1998:44:269
![Page 19: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/19.jpg)
Significantly more drivers with ADHD•drove without a license•had licenses revoked or suspended•had multiple crashes (2+)•had multiple traffic citations (3+), especially for speeding
ADHDMotor Vehicle Driving__________________
Study of 16 to 22 year olds-35 with ADHD (not on medication)-36 controls
Subgroups of ADHD with comorbid oppositional defiant or conduct disorder were at highest risk
Barkley et al. Pediatrics 1993;92-212
![Page 20: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/20.jpg)
Trials SuggestImproved Driving
on Methylpenidate
![Page 21: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/21.jpg)
CURRENT ISSUES REGARDING ADHDSleep Problems
• Sleep problems are common in ADHD
• Poor sleep interferes with concentration
• Sleep apnea does occur in kids and treating it help attention span
• Not clear that sleep apnea is a common cause of ADHD
• Should screen for problems with sleep
![Page 22: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/22.jpg)
Bipolar Disorder
1. Current controversy 2. Relationship of adult to childhood disorder 3. Prevalence in childhood and adolescence 4. Relation of Bipolar disorder to ADHD
![Page 23: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/23.jpg)
Most Important Studies
![Page 24: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/24.jpg)
MTAMultiple Center Study
14 months
![Page 25: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/25.jpg)
Much better outcome with intensive expert treatment vs community clinical results
Study vs Community Comparison
Mean Dose ofmethylphenidate:35mg/day 20mg/dayGiven 3 x day Given 2 x day1 visit per month 1 visit per year30 minute session 18 minute sessionRegular School Contact Rare school contact
![Page 26: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/26.jpg)
Combined behavioral and medication vs medication alone
1) No differences in degree of improvement of ADHD symptoms in combined vs medication
2) Lower doses of medication in combined vs medication alone
3) Better outcome in combined Rx on social skills, aggression, arguing, anxiety, academics
4) Specificity of response outcome related to child (e.g., anxiety) and parental variables (e.g., depression or substance abuse)
![Page 27: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/27.jpg)
MTA - Longer Term Follow-up
1) Effects of active treatment not as robust after closure of trial2) Patients with less morbidity have better outcomes3) Concerns regarding growth on stimulants
![Page 28: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/28.jpg)
PATS – Greenhill, et al
• Preschoolers with ADHD RCT with methylphenidate
![Page 29: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/29.jpg)
PATSResults
• Largest Study To-Date• Positive Response• Lower Doses• Higher Side Effects
![Page 30: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/30.jpg)
TREATMENTTREATMENT
![Page 31: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/31.jpg)
Treatment1) Medication alone is not enough2) Multimodal
a) Medication used judiciously b) Parent and patient education c) School consultation d) Support for family e) Social skill training, behavior management treatment and psychotherapy if indicated
f) Vocational counseling3) Duration of treatment is dependent on duration of symptoms, persistent evidence of response and relative freedom from side effects4) Attention to treatment of comorbid symptoms is essential
![Page 32: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/32.jpg)
Benefits of Psychosocial treatment1) Disruptive symptoms
2) Anxiety/Depressive symptom
3) Tutoring
![Page 33: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/33.jpg)
Considerations• Homework
• After school activities–Sports
–Drama
–Jobs
–Driving
![Page 34: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/34.jpg)
Enduring Interest in Alternative Treatments
• Diet - sugar, red dye
• Biofeed
• Iron and Zinc supplements
• Omega-3 Fatty Acids
No controlled trial evidence of benefit
![Page 35: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/35.jpg)
Medication for ADHD I. Primary - Stimulants
a) Methylphenidate (Ritalin**, Metadate ER**, CD Concerta**, Methylin**)
b) Dextroamphetamine (Dexedrine***, Dextrostat***)
c) Amphetamine/Dextroamphetamine (Adderall***; Vyvanse)
d) Dexmethylphenidate (Focalin)**
** FDA approval to Rx ADHD for children 6 and over *** FDA approval to Rx ADHD for children 3 and over
![Page 36: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/36.jpg)
Medication for ADHD
Secondarya) Atomoxetine (Strattera)b) Alpha - 2 Agonists
1. Clonidine (Catapres*) 2. Guanfacine (Tenex*; Intuniv)
c) Other Antidepressants 1. Bupropion (Wellbutrin*) 2. Venlafaxine (Effexor*)
d) Tricyclic Antidepressants 1. Imipramine (Tofranil*) 2. Nortriptyline (Pamelor*) 3. Desipramine (Norpramin*)
e) Modafinil (Provigil*)
* non FDA approved to Rx ADHD ** FDA approval to Rx ADHD for children 6 and over *** FDA approval to Rx ADHD for children 3 and over
![Page 37: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/37.jpg)
1) Offer hope of once-a-day dosing
2) Better acceptance
3) More costly
Longer Acting Longer Acting StimulantsStimulants
![Page 38: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/38.jpg)
METHYLPHENIDATE 1) Dose: Generally, 5-80mg/day
not more than 2 mg/kg/day2) q.d. to q.i.d. dosing, depending on
patient and form of medication
3) Optimize dosing
4) Side effects a) Decrease in appetite b) Sleep problems c) Tics d) Irritability/Depression 5) Tolerance (can occur with all stimulants), with need
for dose advance or switch to alternative medication
![Page 39: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/39.jpg)
Methylphenidate (continued)
6) Available in multiple preparations:
a) Ritalin 5, 10 and 20mg regular acting; 20mg
sustained release; Ritalin LA 10, 20, 30, 40mg with
50/50 immediate/extended release beads ratio
b) Metadate ER and CD
c) Concerta
d) Methylin: available in 5, 10, 20mg regular
acting methylphenidate and in 10 and 20mg
extended release (ER) tablets
e) Transdermal patch (Daytrana)
![Page 40: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/40.jpg)
Dexmethylphenidate (Focalin)
1) Active isomer of methylphenidate
2) Twice as potent
![Page 41: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/41.jpg)
Focalin XR
1) Capsule: immediate release (IR) and extended release (ER) beads in 50/50 ratio
2) Duration of action 6-12 hours
![Page 42: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/42.jpg)
DEXTROAMPHETAMINE
1) Dose: 5-50mg
2) Generally similar to Methylphenidate; twice
as potent with equal efficacy
3) Available in 5mg (Dexedrine and
Dextrostat) and 10mg tablets (Dextrostat)
and longer acting 5,10 and 15mg spansules
(Dexedrine)
![Page 43: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/43.jpg)
Dextroamphetamine/Amphetamine
1) Combination of amphetamine 25% and
dextroamphetamine 75%
2) Generally similar to methylphenidate, twice as
potent with equal efficacy
3) Duration of action longer than methylphenidate
4) Available in 5,10,20, and 30mg immediate release generic and Adderall tablets, and in long acting generic and Adderall XR- longer acting capsule form
![Page 44: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/44.jpg)
Lis-dexamphetamine Dimesylate Amphetamine prodrug, an amphetamine
bound to lysine
• Inactive initially, converted in gut
• Possibly lower abuse potential re injection or inhalation
• Report of consistent + long duration of action
• FDA approval, 2-07, still as a Schedule II drug
• Brand name Vyvanse
• Released July, 2007
![Page 45: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/45.jpg)
• Dose equivalence to amphetamine not clear, but probably ~ ½ as potent, multiple dose sizes up to 70mg
• No published trials > 70 mg/day• Added benefit vs. Adderall XR not
established• Adderall XR is off patent
![Page 46: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/46.jpg)
SIDE EFFECTS OF SIDE EFFECTS OF STIMULANTSSTIMULANTS
![Page 47: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/47.jpg)
CardiovascularCardiovascular
![Page 48: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/48.jpg)
CASES OF SUDDEN DEATH IN KIDS ON ADHD MEDICATIONS
HAVE BEEN REPORTED
![Page 49: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/49.jpg)
CAUSAL AND CAUSAL AND STATISTICAL LINK STATISTICAL LINK NOT ESTABLISHEDNOT ESTABLISHED
![Page 50: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/50.jpg)
FDA Warning (Not BLACKBOX)
August 2006For All Stimulants
Followed Advisory Panel 2-9-2006 recommendations
– 8-7 vote for the FDA to display a BLACK BOX warning about possible cardiovascular risks though
» “We didn’t find the sudden death data very persuasive”
– 15-0 for FDA to create “Medication Guides” explaining possible risk
» Possible Cardiovascular risks
» Psychiatric side effects, including psychosis
![Page 51: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/51.jpg)
EKG Monitoring• Recommendation to routinely do baseline EKG
made 5-6-08 by the AHA
• Changed shortly thereafter to a class IIB recommendation, by clinician choice
![Page 52: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/52.jpg)
American Heart Association 5/2008
Now a Class IIa recommendation that
children with ADHD get a careful
cardiac evaluation, including an EKG
before starting stimulant, which means it
is reasonable to consider an EKG, but
at the physician’s judgment. It is not
mandatory
![Page 53: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/53.jpg)
Risk of Psychosis
• 1.5 per 100 patient years of exposurePediatrics, January 2009.
![Page 54: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/54.jpg)
Faraone• Faraone S, Biederman J, Morley C, Spencer T. Effect of
stimulants on height and weight: a review of the literature. J Am Acad of Child Adolesc Psychiatry. 2008;47(9):994-1009.
![Page 55: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/55.jpg)
Faraone (continued)• Quantitative analysis of longitudinal studies of growth in
children with ADHD on stimulant medication
![Page 56: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/56.jpg)
Stimulants and Growth• Results of the meta-analysis
– Delay in height and weight.
– Impact of .5-1” over lifetime.
– Attenuation over time.
– Seem to be dose dependent.
– MPH and d-amphetamine are similar.
– Discontinuation can lead to normal growth.
– Do kids with ADHD have different patterns of growth?
![Page 57: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/57.jpg)
Recommendations• Treat one patient at a time regarding appetite/growth
decisions
• Measure height and weight
• Unusual to have to stop or change medication as a result of decreases in growth velocity
• Remember other problems can explain decrease in growth velocity
![Page 58: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/58.jpg)
Intervention if Concerns Arise• No data to inform treatment
• Change diet
• Change meds
• Consider D/C of meds
• Consider endocrinology referral
![Page 59: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/59.jpg)
TICS• Contraindication per FDA
• May not be contraindicated in reality
• Do need to discuss with patients and families
![Page 60: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/60.jpg)
Atomoxetine (Strattera)
1. NA reuptake inhibitor
2. Multiple trials with ADHD benefit in children, adolescents and adults
3. Released January 2003
![Page 61: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/61.jpg)
Atomoxetine
1) Dose for children 1.4mg/kg/day; adult
mean dose 93/mg/day; may need to go
higher
2) qd or bid
3) Metabolized by Cytochrome p450 2D6-
interaction with fluoxetine
![Page 62: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/62.jpg)
ALPHA-2 AGONISTSALPHA-2 AGONISTS
![Page 63: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/63.jpg)
Alpha-2 agonists1. Clonidine a) Dose: .05-.4mg/day; bid to qid; patch (hypersensitivity) b) Primary symptom relief with hyperactivity and
aggression c) May reduce stimulant dose requirement d) Side effects: 1) Sedation 2) Hypotension 3) Depression e) Tolerance is common f) Rebound hypertension is common during withdrawal: tapering is necessary g) Some capacity to reduce tics h) Reports of sudden death in combination with stimulants- not a clear relationship
![Page 64: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/64.jpg)
Alpha-2 Agonists
2. Guanfacine a) Dose: 0.5 to 4.0 mg/day in divided doses b) Similar effect but with longer half-life (18 vs 2 1/2 hours) c) Possibly fewer side effects, especially less sedation vs clonidine
![Page 65: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/65.jpg)
GuanfacineGuanfacine(Intuniv)(Intuniv)
• Long-acting preparation
• Two positive industry sponsored RCTs
• FDA approved, 2009
• No evidence of superiority of Intuniv over multiple doses of immediate release guanfacine
• Contains 60% guanfacine
![Page 66: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/66.jpg)
Alpha 2-agonist• Often used in addition to a stimulant to
address motor restlessness not improved by a stimulant
• Also used for sleep initiation, especially clonidine
![Page 67: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/67.jpg)
Bupropion (Wellbutrin)“Activating “antidepressantDosage: 50-300 mg/day
4 of 5 studies with positive effect Side effects
1) seizures: 4/1000, less with long acting preparation2) agitation3) anorexia4) tics
Now with XL qd preparation
![Page 68: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/68.jpg)
MODAFINIL EFFICACY
• Response rate 60-65%
• Effect size = .75, moderate
• Efficacy similar to atomoxetine, but less than stimulants
![Page 69: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/69.jpg)
Modafinil• Additional safety concerns raised by
the FDA
• Sent back to company for further review of the safety concerns by FDA
• Application then withdrawn by Cephalon
![Page 70: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/70.jpg)
Comparison Studies
![Page 71: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/71.jpg)
Comparison Studies Have All Been
Industry Sponsored
• Have to consider results in that context
![Page 72: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/72.jpg)
Newcorn• Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD,
Moore RJ, et al. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. The American Journal of Psychiatry. 165 (6), 721-30.
![Page 73: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/73.jpg)
Newcorn (continued)Atomoxetine vs. MPH (OROS)
COMPLEX DESIGN• 6 week, double-blind, placebo-controlled parallel design study
trial.
• N=516.• Ages 6-16 years.• ADHD, any subtype.• Atomoxetine: MPH: placebo 3:3:1.• Atomoxetine dose (0.8-1.8 mg/kg/day); mean dose 1.45 mg/kg/day• MPH (OROS) dose 18 – 54 mg/day; mean dose 40 mg/day
![Page 74: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/74.jpg)
Atomoxetine vs. MPH (OROS)
• Response Rates–OROS MPH 56%.
–Atomoxetine 45%.
–Placebo 24%.
![Page 75: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/75.jpg)
Atomoxetine vs. MPH (OROS) (continued)
• After 6 weeks patients switched from MPH (OROS) to Atomoxetine for 6 weeks
• No washout period in transition
![Page 76: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/76.jpg)
Atomoxetine vs. MPH (OROS)
• 43% of Non-Responders to MPH responded to Atomoxetine
• 42% of Non-Responders to Atomoxetine responded to MPH
![Page 77: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/77.jpg)
Summary:1. Both atomoxetine and OROS MPH effective
2. Response greater with OROS MPH
3. Significant percentage of Atomoxetine nonresponders will respond to OROS MPH and vice versa
![Page 78: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/78.jpg)
Metadate CD vs Concerta(COMACS)
•Clinical Effect Correlated with Serum MPH Level•Both Superior to Placebo
![Page 79: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/79.jpg)
Ritalin LA vs ConcertaRitalin LA vs Concerta
•2 studies2 studies•In both studies active drugIn both studies active drug significantly better than placebosignificantly better than placebo
![Page 80: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/80.jpg)
Morning superiority of Morning superiority of Ritalin LA vs ConcertaRitalin LA vs Concerta
![Page 81: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/81.jpg)
Choice and Dosage Choice and Dosage of ADHD of ADHD
MedicationsMedications
![Page 82: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/82.jpg)
IMPORTANT
Two most common mistakes re medication
1.Not optimizing dose
2.Not switching to alternative medication if first agent not helpful
![Page 83: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/83.jpg)
Generally:Generally:Stimulants first, then consider atomoxetine or alpha-2 agonists
![Page 84: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/84.jpg)
Stimulants: Overall
pharmacodynamics are informed by
pharmacokinetics
![Page 85: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/85.jpg)
Need to shape medication plan to
child’s family’s needs re duration of effect
![Page 86: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/86.jpg)
Single Dose/Day may not be Enough
![Page 87: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/87.jpg)
Efficacy of Stimulants
1) About ¾ of patients with ADHD respond to a single stimulant
2) Of the ¼ who don’t respond to one class of stimulant, about ½ will respond to a stimulant of a different class (e.g., amphetamine after methylphenidate or methylphenidate after amphetamine)
3) Response rate to one class of stimulant probably about the same as to another class. Metanalysis by Faraone suggests small advantage of Adderall versus methylphenidate.
![Page 88: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/88.jpg)
FDA Dosage Limits• OROS Methylphenidate (Concerta) 72mg
• Transdermal Methylphenidate (Daytrana) 30mg
• Dexmethylphenidate extended release (Focalinx R) 30mg
• Mixed salts Amphetamine Extended Release (AdderallXR) 40mg
• Amfetamine-lysine (Vyvanse) 70mg
![Page 89: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/89.jpg)
ADHD Symptoms in Autistic Spectrum Disorders
• Emerging evidence for some benefit with:–Methylphenidate
–Guanfacine
–Atomoxetine
• Degree of response is attenuated
![Page 90: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/90.jpg)
Substance AbuseSubstance Abuse
In controlled settings, evidence of benefit with
stimulants
![Page 91: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/91.jpg)
No evidence that No evidence that medication of ADHD medication of ADHD leads to substance leads to substance abuse and may help abuse and may help
prevent itprevent it
![Page 92: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/92.jpg)
Do need to be aware Do need to be aware of diversionof diversion
![Page 93: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/93.jpg)
If concerns re substance abuse by patient/parent or diversion options:
• Atomoxetine
• Vyvanse
• Daytrana
![Page 94: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/94.jpg)
Anxiety and ADHD Controlled Trials
• Benefit with stimulants
• Benefit with atomoxetine
![Page 95: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/95.jpg)
Treat first things Treat first things firstfirst
![Page 96: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/96.jpg)
Essentially no clinical effectiveness trials at
higher doses and trials show side effects
![Page 97: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/97.jpg)
In practice higher doses are prescribed
![Page 98: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/98.jpg)
In general, the higher the dose the more cautious in approach to cost/benefit
guidelines
![Page 99: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/99.jpg)
•Recent Trials Indicate Recent Trials Indicate Benefit of Combining Benefit of Combining Stimulant and AtomoxetineStimulant and Atomoxetine
•Should be reserved for Should be reserved for cases with failure to cases with failure to respond to single agentsrespond to single agents
![Page 100: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/100.jpg)
Combinations of Medications1) To manage partial response to ADHD
e.g., 1) Can’t sustain effect
2) Side effect management
e.g., 1) sleep disturbance
2) rebound
3) moodiness or irritability
3) Comorbid disorders
![Page 101: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/101.jpg)
Combined Pharmacotherapy
Common practice
Practice far exceeds data
base, controlled or open
trials
![Page 102: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/102.jpg)
SUMMARYSUMMARY
![Page 103: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/103.jpg)
Practical Points
1. Optimize ADHD Treatment
2.Monitor Target Symptoms + Side Effects
3.Then Attend to Comorbid Disorders
![Page 104: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/104.jpg)
How Long Do you Treat?• Common illness with high potential for
chronicity
• No set end point
• Usually Rx successfully through a whole school year
• Periodic analysis of cost/benefit analysis
• Periodic effort to withdraw
![Page 105: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/105.jpg)
REFERENCESAmerican Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad child Adolesc Psychiatry. 1997;36:1-15.
American Academy of Pediatrics. Clinical practice guidelines: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170.
American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
![Page 106: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/106.jpg)
Angold A, Erkanli A, Egger HL, et al. Stimulant treatment for children: A community perspective. J Amer Acad Child Adoles Psych 2000;39:975-984
Beiderman J, Klein RG, Pine DF, Klein DF. Mania is mistaken for ADHD in prepubertal children. Affirmative: J Am Acad child Adolesc Psychiatry. 1998;37(10):1091-1093.
Jensen PS, Kettle L, Roper MT., et al. Are stimulants over prescribed? Treatment of ADHD in four U.S. communities. J Amer Acad Child Adoles Psych 1999;38:797-804.
![Page 107: Evidence Based Assessment and Treatment of Attention Deficit Hyperactivity Disorder May 14, 2010 Christopher K. Varley, M.D](https://reader034.vdocument.in/reader034/viewer/2022042821/56649d4b5503460f94a28d68/html5/thumbnails/107.jpg)
MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073-1086.
ADHD A Complete and Authoritative Guide. Michael I. Reife, M.D., FAAP, Editor with Sherill Tippins. Amer Acad Pediatrics 2003.